CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Stable CH505TF gp120 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03856996
NCT03856996Phase 1Completed
CompareCT.gov

A Phase 1 Double-blind, Randomized, Controlled Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Feb 27, 2019·Updated Jul 12, 2024

In Brief

A Phase 1 clinical trial evaluating Stable CH505TF gp120, Transient CH505TF gp120, and 1 other intervention for HIV Infections. Completed, enrolled 30 participants across 3 sites.

Detailed Summary

The purpose of this study is to compare the safety, tolerability, and immunogenicity of CH505TF gp120 produced from stably transfected cells to CH505TF gp120 produced from transiently transfected cells in healthy, HIV-1-uninfected adult participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedFeb 27, 2019
Enrollment StartMay 23, 2019
Primary CompletionMar 16, 2021
Study CompletionSep 7, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.3 years ago

Interventions

Stable CH505TF gp120biological

Administered by IM injection in the deltoid of the non-dominant arm

Transient CH505TF gp120biological

Administered by IM injection in the deltoid of the non-dominant arm

Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)biological

Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm